CMS ends federal Medicaid and CHIP match for youth gender transition care Oct. 13, with a 6-month hormone taper

CMS has finalized a rule that cuts off federal matching funds for puberty blockers, cross-sex hormones and surgery used in gender transition for children enrolled in Medicaid and CHIP. The rule, CMS-2451-F, was released August 11, published August 13 and takes effect October 13, 2026 [1, 2].

The practical test it creates is unusual. The same drug can be payable or not depending on what it was prescribed for, and CMS acknowledges that a standard outpatient pharmacy claim carries no diagnosis code to tell the difference [1].

What changed

State Medicaid plans must now provide that the agency will not pay for what the rule calls “sex-rejecting procedures” for children under 18, and federal financial participation is unavailable for those expenditures [1]. Separate CHIP programs face the same bar for children under 19, because CHIP law defines a child as anyone under 19 [1].

The definition covers any pharmaceutical or surgical intervention that tries to align a person’s body with an identity that differs from their sex, either by suppressing normal development or by altering the body [1]. It excludes treatment of a medically verifiable disorder of sexual development, procedures done for any other purpose, and care for complications of earlier procedures [1].

CMS made two changes from its December 19, 2025, proposal. It added a tapering period: for beneficiaries receiving cross-sex hormone therapy on October 13, states may keep claiming federal funds for those hormones for up to 6 months [1]. And it swapped “child” for “individual” in the definition, since the age limits sit elsewhere in the regulation [1]. CMS said it received about 11,000 timely comments, more than 90% opposed [1].

The agency rests the rule on two Social Security Act requirements: that Medicaid care serve recipients’ best interests, under section 1902(a)(19), and that payments be consistent with quality of care, under section 1902(a)(30)(A) [1]. It cites a November 2025 HHS evidence review and the United Kingdom’s Cass Review [1].

Who it affects

The money is modest by Medicaid standards. CMS found about $31 million in combined federal and state Medicaid and CHIP spending on these services for patients 17 and younger in 2023 [1]. KFF puts that at 0.003% of all Medicaid spending that year [3]. Hormone therapy for ages 6 through 17 accounted for $23.8 million, and 88% of that, $21.0 million, went to GnRH analogues, the drugs used as puberty blockers [1].

CMS projects total savings of $235 million over 10 years: $138 million federal and $97 million state, in real 2027 dollars [1].

The effect lands in states that still cover the care. Twenty-seven states and Puerto Rico have laws restricting these procedures for minors, and states without bans accounted for 76% of the 2023 spending [1]. AJMC reported that about 17 state Medicaid programs currently cover one or more of the services [4]. KFF estimates about 130,000 transgender young people with Medicaid or CHIP live in states without restrictions [3].

Surgery is concentrated in large hospitals. CMS cites a study finding 88.4% of patients identified as having these surgeries were treated at urban teaching hospitals, and it reviewed a list of 42 provider organizations that had stopped or planned to phase out the services; three-fourths were part of academic medical centers or teaching hospitals [1].

How will Medicaid tell a puberty blocker for precocious puberty from one for gender dysphoria?

By purpose, and mostly through prior authorization. CMS states that GnRH analogues for precocious puberty, hormone therapy for growth hormone deficiency and treatment for cancer, endometriosis or hypogonadism are not affected [1].

The agency concedes the operational gap. The rule says “standard outpatient pharmacy claims do not currently include diagnosis codes,” which “may make it difficult to determine at the point of dispensing” why a drug is being given [1]. CMS expects “prior authorization processes and utilization management tools” to be the main way states keep federal funds off these claims [1].

States may not simply drop the drugs. Because the products are approved for other indications, they must stay coverable for those uses under section 1927 of the Act, and nothing in the rule requires states to remove them from formularies [1].

What it means for your practice

Your hormone patients get a fixed runway. Take a 16-year-old Medicaid patient on testosterone before October 13. The state can draw federal match for that prescription for up to 6 months from October 13, 2026, which reaches into mid-April 2027 [1]. A patient who would have started hormones in November gets no federal match at all, and the taper never covers puberty blockers or surgery [1]. CMS says the 6 months “is not intended to serve as a clinical guideline” and that clinicians may judge a shorter taper appropriate [1].

Your documentation decides payment. With a purpose-based test, the indication on your order and in the chart is what a prior authorization reviewer will see. An endocrinology practice treating both central precocious puberty and gender dysphoria with the same drug should expect its notes to be read closely.

Your state’s choice matters more than the federal rule. States may keep paying with state-only funds, and the rule does not stop private insurance or self-pay [1]. Where a state declines, the payment simply stops at the Medicaid line. CMS estimated state policy-review costs only for the 28 states and territories without existing bans [1].

Other services stay payable. Counseling, psychotherapy and other mental health care for gender dysphoria keep federal funding, and CMS says EPSDT continues to require coverage of children’s mental health services [1, 2, 6]. The rule also states that it does not limit providers’ ability to discuss treatment options with patients [1].

What to do now

1. Build your patient list. Identify Medicaid and CHIP patients under 18, or under 19 in a separate CHIP, on cross-sex hormones, GnRH analogues or awaiting surgery, and note who will be on hormones on October 13 [1].
2. Clean up indication documentation. Make the diagnosis and purpose explicit on orders for GnRH analogues, testosterone and estrogen, including for precocious puberty, hypogonadism and disorders of sexual development [1].
3. Call your state and plans. Ask the Medicaid agency and each managed care plan whether they will use state-only funds, and when they will change prior authorization criteria. CMS expects states to file state plan amendments and says the work is “well within the normal operational capacity” of Medicaid agencies [1].
4. Talk with your pharmacy partners. Pharmacies will see claims for these drugs without diagnosis codes, so agree on how the indication will travel with each prescription [1].
5. Plan referrals for behavioral health. CMS encourages states to make sure patients coming off hormones have access to mental health services during and after the taper [1].

The policy fight

The administration frames the rule as patient safety. “These interventions carry serious risks and can cause irreversible harm,” HHS Secretary Robert F. Kennedy Jr. said [2]. CMS Administrator Mehmet Oz said: “By cutting off federal funds for these sex-rejecting procedures, we’re following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm” [2]. CMS also pointed to a February 2026 American Society of Plastic Surgeons position statement as a sign that professional consensus is moving [4, 5].

Opponents say the evidence points the other way. KFF notes that the American Medical Association, the American Academy of Pediatrics and the American Psychological Association recommend the care [3]. Human Rights Campaign President Kelley Robinson said every young person is entitled to care “that they, their parents, and their medical providers agree that they need, without politicians interfering” [5]. Rep. Mark Takano of California, chair of the Congressional Equality Caucus, called it “just another cruel, overreaching attack” [4]. Advocates for Trans Equality warned of clinic closures and delayed care, especially for rural families [4].

Commenters also asked for more time. Some urged a 12-month taper or an effective date no earlier than January 2027; CMS settled on 6 months and the statutory 60-day delay [1].

Courts are the open question. CMS argues the rule does not conflict with preliminary injunctions issued in Washington and Maryland against parts of two 2025 executive orders, because it rests on separate legal authority [1]. KFF expects litigation; state attorneys general and the ACLU said when the rule was proposed that they would fight it [3].